Has John Bird received payments from drug or device companies?

Yes. Drug and device makers reported $35,867 in general payments to John Bird across 68 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Bird did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Bird come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Bird

Pediatric Allergy/Immunology · Dallas, TXNPI 1851592752

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $29,391 of the $35,867 with a category attached, or 81.9%. 14 manufacturers reported payments, led by Genentech USA, Inc. at 49.5% of the total. Among pediatric allergy/immunology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$35,867in general payments, 2019–2025

Across 68 payments — averaging $527.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Genentech USA, Inc.$18K
Novartis$10K
Genentech, Inc.$7K
AstraZeneca$606
AbbVie$254
Grifols USA, LLC$156
plus $520 from 8 others

$372,587in research payments, 2019–2025

Across 76 payments — averaging $4902.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$235K
Aimmune Therapeutics, Inc.$136K
F. Hoffmann-la Roche AG$1K

What the payments were for

Consulting fees$29,39182%
Travel & lodging$3,0849%
Food & beverage$3,3589%
Education$340%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Genentech USA, Inc.	18	$17,739
Novartis	11	$9,598
Genentech, Inc.	10	$6,994
AstraZeneca	6	$606
AbbVie(2 entities)	13	$254
Grifols USA, LLC	1	$156
Sanofi	1	$132
Blueprint Medicines Corporation	1	$122
ARS Pharmaceuticals Operations, Inc.	1	$94
Alk-abello, Inc	1	$55
Sanofi-aventis U.S. LLC	2	$36
Amgen	1	$34
Pfizer	1	$28
Nestle Healthcare Nutrition Inc.	1	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

XOLAIR$33,594
TEZSPIRE$212
Xembify$156
DUPIXENT$132
AYVAKIT$122
FASENRA$115

How this compares

$35,867 in reported general payments places this provider in the 90th percentile of 29 pediatric allergy/immunology providers in Texas.

See all pediatric allergy/immunology providers in Texas →

Other pediatric allergy/immunology in Dallas

Christopher ParrishDallas$16K
Timothy ChowDallas$11K
Gaytri PatelDallas$3K
Jeffrey ChamblissDallas$2K
Rory NicolaidesDallas$1K
Kyle RobillardDallas$475
Lisa SatterHouston$225K
Niti ChokshiHouston$47K
Imelda HansonHouston$34K
Aikaterini AnagnostouHouston$33K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →